PellePharm Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

PellePharm General Information

Description

Developer of skin cancer therapeutics intended to mitigate the tumor burden with basal cell carcinomas. The company's therapeutics include topical hedgehog inhibitor which decreases the number of surgically-eligible basal cell carcinomas in Gorlin syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.

Contact Information

Website
www.pellepharm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 Mission Street
  • Suite 1950
  • San Francisco, CA 94105
  • United States
+1 (510)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 101 Mission Street
  • Suite 1950
  • San Francisco, CA 94105
  • United States
+1 (510)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PellePharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Apr-2023 Completed Generating Revenue
6. Later Stage VC 20-Nov-2018 Completed Generating Revenue
5. Later Stage VC (Series C) 18-Jun-2018 Completed Generating Revenue
4. Debt - General 29-Mar-2018 Completed Generating Revenue
3. Later Stage VC (Series B2) 31-Jul-2017 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Jul-2015 $4.55M $7.67M Completed Generating Revenue
1. Early Stage VC (Series A) 11-May-2015 $3.12M $3.12M Completed Generating Revenue
To view PellePharm’s complete valuation and funding history, request access »

PellePharm Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B2
Series B 3,888,889 $0.000100 $0.09 $1.17 $1.17 1x $1.17 8.67%
Series A 3,712,649 $0.000100 $0.84 $0.84 1x $0.84 8.27%
To view PellePharm’s complete cap table history, request access »

PellePharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of skin cancer therapeutics intended to mitigate the tumor burden with basal cell carcinomas. The company's th
Biotechnology
San Francisco, CA
8 As of 2021

Branford, CT
 

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PellePharm Competitors (28)

One of PellePharm’s 28 competitors is Azitra, a Formerly VC-backed company based in Branford, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Azitra Formerly VC-backed Branford, CT
MatriSys Bioscience Venture Capital-Backed La Jolla, CA
Bolden Therapeutics Venture Capital-Backed Providence, RI
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
Naked Biome Formerly VC-backed San Francisco, CA
You’re viewing 5 of 28 competitors. Get the full list »

PellePharm Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

PellePharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170231968-A1 Method for relief of and treatment of pruritus Inactive 11-Feb-2016
JP-6796638-B2 Topical formulations and their use for the delivery of hedgehog inhibitory compounds Active 04-Jun-2015
JP-2021014469-A Topical formulations for delivery of hedgehog inhibitor compounds and uses thereof Pending 04-Jun-2015
JP-2018516989-A Topical formulations for the delivery of hedgehog inhibitory compounds and uses thereof Active 04-Jun-2015 A61K31/496

PellePharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PellePharm Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
LEO Pharma PE-Backed Company Minority
Aisling Capital Venture Capital Minority
EcoR1 Capital Venture Capital Minority
Angel (individual) Minority
BridgeBio Pharma Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

PellePharm Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
PellePharm (Hedgehog Signaling Pathway Blocker in San Francisco) San Francisco, CA

PellePharm FAQs

  • When was PellePharm founded?

    PellePharm was founded in 2012.

  • Where is PellePharm headquartered?

    PellePharm is headquartered in San Francisco, CA.

  • What is the size of PellePharm?

    PellePharm has 8 total employees.

  • What industry is PellePharm in?

    PellePharm’s primary industry is Biotechnology.

  • Is PellePharm a private or public company?

    PellePharm is a Private company.

  • What is PellePharm’s current revenue?

    The current revenue for PellePharm is .

  • How much funding has PellePharm raised over time?

    PellePharm has raised $113M.

  • Who are PellePharm’s investors?

    LEO Pharma, Aisling Capital, EcoR1 Capital, , and BridgeBio Pharma are 5 of 7 investors who have invested in PellePharm.

  • Who are PellePharm’s competitors?

    Azitra, MatriSys Bioscience, Bolden Therapeutics, Vertex Pharmaceuticals, and Naked Biome are some of the 28 competitors of PellePharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »